MPI Research Invests in an Additional Gyrolab™ xP Workstation

22 May 2012, Uppsala, Sweden and Chalfont St Giles, UK: Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, today announced that MPI Research (www.mpiresearch.com) has become the first contract research organization (CRO) in North America to secure a second Gyrolab™ xP workstation, a nanoliter-scale immunoassay platform.

Data from immunoassays underpin many critical decisions within complex workflows for the development of biopharmaceuticals. The automated, precise, nanoliter-scale immunoassay platform from Gyros enables project-specific biomarker, pharmacokinetic (PK), immunogenicity assays and impurity tests to be developed quickly, and to easily transfer the running of established assays. Since installing its first Gyrolab xP workstation in April 2011, MPI Research has developed more than 25 novel assays using the platform. The ability to work with nanoliter volumes maximises the number of assays that can be performed on samples that are often scarce.

Roger Hayes, PhD, Vice President and General Manager of Laboratory Sciences at MPI Research, commented: “Part of our mission is to exceed expectations, which means investing in innovative technology that can make a real difference to the way we work. We have seen great success both scientifically and commercially with the Gyrolab workstation, and look forward to building on this with additional platforms.”

Erik Walldén, CEO, Gyros, added: “We are very pleased that MPI Research has seen success with the Gyrolab platform. With the growing trend for outsourcing to CRO’s, we are also seeing these companies increasing their capacity for our technology.”

About Gyros AB www.gyros.com

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The Gyros™ immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nanoliter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is, based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors in Asia Pacific.

About MPI Research

MPI Research, with global headquarters in Michigan, provides discovery, safety evaluation, and bioanalytical and analytical testing services (formulation development, regulated bioanalysis, immunochemistry, metals analysis, and environmental analysis) to the biopharmaceutical, medical device, animal health, agricultural, environmental, and chemical industries. Scientific knowledge and experience, quick turnaround, and dedication to strong and enduring customer relationships characterize MPI Research as a high-performance, high-quality organization committed to bringing safer and more effective products to the world. Learn more about how we can exceed your expectations at www.mpiresearch.com.

Enquiries:

For Gyros AB

Katie Odgaard

Zyme Communications Ltd

Tel: +44 (0) 7787 502 947

Email: katie.odgaard@zymecommunications.com

Skype: kodgaard

Web: www.zymecommunications.com

Twitter: zymecomms

For MPI Research

Mark Cameron

Senior Manager of Discovery PK

MPI Research

Tel: +1 269 668 3336, ext. 22193

Email: mark.cameron@mpiresearch.com

Web: www.mpiresearch.com

Back to news